A study evaluating spatial heterogeneity showed that, while IDH-mutant gliomas have homogeneous methylation-based classification, intratumor variability in DNA methylation within glioblastomas, IDH-wild-type, and meningiomas can potentially affect tumor classification of these methylation-based biomarkers [24]. This evidence concerns the gene IDH1 and neoplasm.